KKR-backed Biosynth Carbosynth acquires Vivitide
KKR closes its previously-announced acquisition of Biosynth Carbosynth and announces Biosynth's acquisition of vivitide.
Investment firm KKR has closed its acquisition of UK life sciences company Biosynth Carbosynth, and announced Biosynth's acquisition of vivitide, which provides custom peptides and antibodies for the biotech industry.
Previous vivitide owner Ampersand Capital Partners will become a minority stakeholder in the combined entity. KKR and Ampersand say they plan to accelerate the company’s geographic expansion, broaden its capabilities and expand its product portfolio.
KKR utilized a $4 billion strategic growth fund focused on high-growth health care companies to invest in Biosynth Carbosynth. Company leadership believe the move will position Biosynth Carbosynth as a premium global platform serving high-growth end markets in the life sciences.
Speaking on the acquisition, Biosynth Carbosynth CEO Dr. Urs Spitz said the deal marks an “important milestone” in the company’s journey, adding that Biosynth will “benefit greatly from vivitide’s strong U.S. presence, complementary portfolio of products and services, and entrepreneurial culture.”
Vivitide CEO Dr. Martina Diekmann said she was proud to join forces with Biosynth, noting that the acquisition will allow an acceleration of growth and expanded product offering.
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
.png)
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
.png)
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
.png)
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
.png)
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
.png)
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance